Table 3. Results of univariate analysis for two-year OS, LRFS, and DMFS.

OS = overall survival; LRFS = local recurrence-free survival; DMFS = distant metastasis-free survival; NLR = neutrophil to lymphocyte ratio; SII = systemic inflammation index; SBRT = stereotactic body radiation therapy; BED = biologically equivalent dose; CHT = chemotherapy; FOLFIRINOX = leucovorin calcium (folinic acid), fluorouracil, irinotecan hydrochloride, and oxaliplatin

Variable	OS (%)	P-value	LRFS (%)	P-value	DMFS (%)	P-value
Age (years)
≤64	50	0.164	48	0.413	40	0.280
>64	23		22		13
Sex
Male	44	0.525	43	0.433	30	0.945
Female	38		22		33
Tumor size
≤3.5 cm	58	0.042	57	0.029	39	0.019
>3.5 cm	14		10		12
CA 19-9
≤106.5 kU/L	58	0.006	56	0.021	50	0.019
>106.5 kU/L	12		11		0
NLR
≤2.1	14	0.117	12	0.100	13	0.283
>2.1	60		57		39
SII
≤615.5	46	0.474	45	0.291	41	0.348
>615.5	25		23		15
SBRT dose
≥35 Gy	46	0.536	44	0.649	38	0.621
<35 Gy	25		24		15
BEDα/β10Gy
≥60 Gy	43	0.325	40	0.447	37	0.871
<60 Gy	38		39		18
Neoadjuvant CHT
Yes	39	0.782	38	0.794	28	0.781
No	35		34		33
Neoadjuvant CHT regimen
Gemcitabine	38	0.899	36	0.839	25	0.945
FOLFIRINOX	40		39		31
Concurrent CHT
Yes	22	0.266	21	0.249	21	0.249
No	43		39		42
Adjuvant CHT
Yes	37	0.619	36	0.928	31	0.381
No	33		30		28
Adjuvant CHT regimen
Gemcitabine	41	0.177	39	0.329	34	0.483
FOLFIRINOX	39		33		27